Exited position

Chase Coleman’s Eli Lilly (LLY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Tiger Global Management LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2023Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares1.51MHighest verified quarter-end share count
Quarters reported9Verified quarters with shares above zero
What happened?

Tiger Global Management LLC first reported Eli Lilly in Q2 2023. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Tiger Global Management LLC sold the entire position in Q3 2025, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2025
Sold the entire position−1.51M shares · No shares reported at quarter-end
Q2 2025
Bought 13.2% more+176.20K shares · 1.51M shares reported after the change
Filing context

Quarter-end price $779.53 · Estimated holding basis $610.35

Q1 2025
Bought 1.9% more+25.00K shares · 1.33M shares reported after the change
Filing context

Quarter-end price $825.91 · Estimated holding basis $588.02

Q4 2024
Bought 35.1% more+340.16K shares · 1.31M shares reported after the change
Filing context

Quarter-end price $772.00 · Estimated holding basis $583.48

Q3 2024
Bought 4.3% more+39.80K shares · 969.80K shares reported after the change
Filing context

Quarter-end price $885.94 · Estimated holding basis $517.36

Q2 2024
Bought 4.5% more+40.00K shares · 930.00K shares reported after the change
Filing context

Quarter-end price $905.38 · Estimated holding basis $501.59

1 unchanged quarter is collapsed by default.

Portfolio importance

How important was Eli Lilly in Tiger Global Management LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight3.5%Q2 2025
Last reported rank#8of 50 reported positions
Peak portfolio weight4.1%Q1 2025
Best historical rank#8Q1 2025
At peak importanceQ1 2025
LLY
4.1%
Largest holding
16.2%
Cross-investor discovery

Who else owns Eli Lilly?

Also reported by 5 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
LLY0.6% of reported portfolio
Ray DalioBridgewater Associates, LP
LLY0.4% of reported portfolio
George SorosSoros Fund Management
LLY0.3% of reported portfolio
Explore Eli Lilly across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$1,115.702026-09-11

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Eli Lilly stock page →

This tracker follows Tiger Global Management LLC’s Form 13F disclosures, not Chase Coleman’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.